Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain
Objective: Splenectomy, thrombopoietin receptor agonists and rituximab are the second-line treatments for steroid-resistant adult primary immune thrombocytopenia. The last two are becoming the most widely used treatments to avoid splenectomy adverse effects and inconveniences. However, the choice...
Main Authors: | Eduardo Anguita, Francisco Javier Parrondo García, José Ramón González-Porras |
---|---|
Format: | Article |
Language: | English |
Published: |
Grupo Aula Médica
2020-11-01
|
Series: | Farmacia Hospitalaria |
Subjects: | |
Online Access: | http://www.aulamedica.es/fh/pdf/11525.pdf |
Similar Items
-
Successful treatment with eltrombopag in avoiding splenectomy for patients with chronic refractory immune thrombocytopenia
by: Alhossain A. Khalafallah, et al.
Published: (2012-01-01) -
The Use of High Dose Eltrombopag in the Management of Sepsis-Associated Thrombocytopenia in Critically Ill Patients
by: Hasan Md. Jahidul, et al.
Published: (2019-11-01) -
Use of Eltrombopag in Children With Chronic Immune Thrombocytopenia (ITP): A Real Life Retrospective Multicenter Experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP)
by: Paola Giordano, et al.
Published: (2020-02-01) -
Use of thrombopoietin receptor agonists in childhood immune thrombocytopenia
by: Angelica Maria Garzon, et al.
Published: (2015-08-01) -
Eltrombopag Use for Treatment of Thrombocytopenia in a Patient with Chronic Liver Disease and Portal Vein Thrombosis: Case Report
by: Sabah E. Mohamed, et al.
Published: (2020-07-01)